UTHR News and Press, United Therapeutics Corporation From 10/11/22

Second registration study of Tyvaso ® (treprostinil) Inhalation Solution for patients with IPF United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study...

For further details see: United Therapeutics initiated at outperform at Wedbush on growth and innovation

Report available at corporateresponsibility.unither.com United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation ( PBC ), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders...

Summary In their legal war, UTHR seems to have won a key battle as opposed to Liquidia. This has pushed back LQDA's launch by 18 months. I consider this a singular setback for the underdog. Liquidia's ( NASDAQ: LQDA ) Tyvaso competitor Yutrepia won a tentativ...

New company will leverage 3D Systems’ recent breakthroughs in bioprinting of vascularized human organs and tissues to accelerate new drug development, reduce costs, and ultimately reduce or eliminate the need for animal testing Unique bioprinted organ-on-a-chip platform, h-VIOS...

One of the more volatile healthcare stocks of recent days, Liquidia Technologies (NASDAQ: LQDA) , had quite the up session on Friday. Investors lifted the share price of the drug developer by almost 21%, following a series of relatively small but confidence-boosting insider buys. ...

Summary Once a highly speculative, non-revenue generating biotech on the verge of bankruptcy MNKD has de-risked much of the previous market concerns over bankruptcy, debt and credit issues. Their flagship product sold under the brand name AFREZZA is the only FDA approved rapid act...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics’ U.S. patents 9,593,066 (the ’...

Luquidia Corp.'s ( NASDAQ: LQDA ) 29 % drop on a judge decision to d eny a stay request on the '793 patent pending appeal of the PTAB's decision appears to be well overdone, according to analysts. "While a negative headline, we don’t view the stay denial as a ...

Summary Tyvaso is being explored by United Therapeutics Corporation in the TETON program (two phase 3 studies) which will determine if label expansion for idiopathic pulmonary fibrosis can be achieved. Tyvaso in an ad-hoc analysis in the short 16-week INCREASE study was shown to i...